Alcohol Use Disorder Drug Shows Promise

Share this content:
CDC rank alcohol-attributable mortality as the third leading cause of preventable death in the United States.
CDC rank alcohol-attributable mortality as the third leading cause of preventable death in the United States.

HealthDay News — An experimental drug -- a vasopressin antagonist called ABT-436 -- shows some promise in treating alcohol use disorder and smoking, according to a study published online in Neuropsychopharmacology.

Researchers at the U.S. National Institutes of Health's National Institute on Alcohol Abuse and Alcoholism (NIAAA), assessed the drug in a 12-week clinical trial that included 144 adults with alcohol use disorder (AUD). Men in the study had at least 35 drinks a week and women had at least 28 drinks a week. Participants were randomly selected to receive either ABT-436 or placebo. Those who took the drug had more days without drinking than those who took the placebo, the researchers found.

Participants with high stress levels appeared to have a stronger response to ABT-436, the investigators said, noting a drop in the frequency of their drinking and the number of heavy drinking days. However, the overall decline in heavy drinking days was not statistically significant between the ABT-436 and the placebo groups.

"Our findings suggest that future studies of ABT-436 should focus on populations of people with alcohol use disorder who also report high levels of stress," first author Megan Ryan, of the NIAAA, said in a journal news release. The study also found that ABT-436 reduced smoking among the participants. The drug might target the same brain areas linked with withdrawal and stress, and have an impact on both tobacco and alcohol use disorders, the researchers said.

Reference

Ryan ML, Falk DE, Fertig JB. A phase 2, double-blind, placebo-controlled randomized trial assessing the efficacy of ABT-436, a novel V1b receptor antagonist, for alcohol dependence. Neuropsychopharmacology. 2016. doi: 10.1038/npp.2016.214 [Epub ahead of print]

You must be a registered member of Psychiatry Advisor to post a comment.

Sign Up for Free e-newsletters